Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Summary of Evidence. Table 1. Summary of Cardiovascular Disease Meta-analyses

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force (USPSTF) > Guide to Clinical Preventive Services, 2001-2004 > Hormone Replacement Therapy > Summary of Evidence

Table 1. Summary of Cardiovascular Disease Meta-analyses

Condition		Relative Risk According to Use of Hormone Replacement Therapy (95% CI)*
Condition		Current	Past	Ever	Any
Mortality	Total cardiovascular disease**	0.64 (0.44-0.93)	0.79 (0.52-1.09)	0.81 (0.58-1.13)	0.75 (0.42-1.23)
	Coronary heart disease	0.62 (0.40-0.90)	0.76 (0.53-1.02)	0.81 (0.37-1.60)	0.74 (0.36-1.45)
	Stroke			0.81 (0.71-0.92)
Incidence	Total cardiovascular disease	1.27 (0.80-2.00)	1.26 (0.79-2.08)	1.35 (0.92-2.00)	1.28 (0.86-2.00)
	Coronary heart disease	0.80 (0.68-0.95)	0.89 (0.75-1.05)	0.91 (0.67-1.33)	0.88 (0.64-1.21)
	Coronary heart disease adjusted for socioeconomic status	0.97 (0.82-1.16)	1.07 (0.90-1.27)	1.11 (0.84-1.53)	1.04 (0.79-1.44)
	Overall stroke			1.12 (1.01-1.23)
	Thromboembolic stroke			1.20 (1.01-1.40)
	Subarachnoid stroke			0.80 (0.57-1.04)
	Intracerebral stroke			0.71 (0.25-1.29)

*Current users are those using estrogen at the time of assessment, past users are those who used estrogen previously but not at the time of assessment, ever users includes current and past users, and never users have not used estrogen at any time. We also created a category, all use, that combines all mutually exclusive types of use (ever, past, and current) for purposes of pooling studies in the meta-analysis.

**Includes multiple cardiovascular outcomes such as coronary heart disease, stroke, sudden cardiac death, and congestive heart failure.

Return to Document